Skip to main content
Premium Trial:

Request an Annual Quote

Dallas Company To Develop Microbial Genome Scanning Tool for Vaccine Discovery

NEW YORK, Feb 8 – Eliance Biotechnology of Dallas has gained exclusive rights to develop large-scale genetic screening technology from The Center for Biomedical Inventions at University of Texas Southwestern Medical Center, the university announced Thursday.

The technology, called “Expression Library Immunization,” is designed to screen bacterial and viral genomes for vaccines and other agents with potential immunological value.

This vaccine development technique “differs from conventional vaccine development approaches, which simply build on already existing knowledge,” said Dennis Stone, UT Southwestern’s vice president for technology development, in a statement. “ELI takes a step back and examines every possible antigen within any pathogen for its ability to provide immune protection against the pathogen.”

This technology can take advantage of a rapidly growing library of publicly available bacterial and viral genomes. In the past ten years, 37 microbial genomes have been completely sequenced and published, and there are 128 microbial genome projects are currently in process, according to Sandra Clifton of at Washington University School of Medicine's Genome Sequencing Center, who gave a presentation at the Advances in Genome Biology and Technology conference in Marco Island, Fla.earlier this week.

Eliance, a start-up genomics company, has been funded by $2.5 million in private financing from Audax Ventures, BioAsia Partners and StarTech Early Ventures.

UT Southwestern established its Center for Biomedical Inventions in 1998 as a way to facilitate commercialization of the university’s inventions within the Dallas metro area.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.